HK1055605A1 - Materials and methods relating to protein aggregation in neurodegenerative disease - Google Patents
Materials and methods relating to protein aggregation in neurodegenerative diseaseInfo
- Publication number
- HK1055605A1 HK1055605A1 HK03107838.8A HK03107838A HK1055605A1 HK 1055605 A1 HK1055605 A1 HK 1055605A1 HK 03107838 A HK03107838 A HK 03107838A HK 1055605 A1 HK1055605 A1 HK 1055605A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- precursor protein
- fragment
- cell
- materials
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000463 material Substances 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 9
- 108090000623 proteins and genes Proteins 0.000 abstract 9
- 239000002243 precursor Substances 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 6
- 230000002776 aggregation Effects 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000008569 process Effects 0.000 abstract 2
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000276398 Opsanus tau Species 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000008859 change Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0101049.5A GB0101049D0 (en) | 2001-01-15 | 2001-01-15 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PCT/GB2002/000153 WO2002055720A2 (fr) | 2001-01-15 | 2002-01-15 | Materiaux et methodes permettant l'agregation des proteines dans une maladie neurogenerative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1055605A1 true HK1055605A1 (en) | 2004-01-16 |
Family
ID=9906862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK03107838.8A HK1055605A1 (en) | 2001-01-15 | 2003-10-30 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| HK11103782.3A HK1149588A1 (en) | 2001-01-15 | 2011-04-14 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11103782.3A HK1149588A1 (en) | 2001-01-15 | 2011-04-14 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7335505B2 (fr) |
| EP (2) | EP2305823B1 (fr) |
| JP (2) | JP4422407B2 (fr) |
| CN (1) | CN1496404B (fr) |
| AT (1) | ATE483814T1 (fr) |
| AU (1) | AU2002225147B2 (fr) |
| CA (2) | CA2697520C (fr) |
| DE (1) | DE60237874D1 (fr) |
| DK (2) | DK1352077T3 (fr) |
| ES (2) | ES2407204T3 (fr) |
| GB (1) | GB0101049D0 (fr) |
| HK (2) | HK1055605A1 (fr) |
| PT (2) | PT2305823E (fr) |
| WO (1) | WO2002055720A2 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| EP1521831B1 (fr) * | 2002-07-12 | 2008-04-09 | Axon Neuroscience Forschungs- und Entwicklungs Gmbh | Animal transgenique exprimant la proteine tau tronquée de la maladie d'alzheimer |
| CN101084204B (zh) | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| AU2013200732B2 (en) * | 2006-03-29 | 2015-04-09 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
| PL2853293T3 (pl) * | 2006-03-29 | 2018-05-30 | Wista Laboratories Ltd. | Związki tioniny i ich zastosowanie |
| DK2013191T6 (en) * | 2006-03-29 | 2019-04-23 | Wista Lab Ltd | 3,7-Diamino-10H-phenothiazine salts and their use |
| CA2645946C (fr) * | 2006-03-29 | 2014-04-01 | Wista Laboratories Ltd. | Inhibiteurs de l'agregation de proteines |
| PT2457904E (pt) | 2006-07-11 | 2015-02-27 | Wista Lab Ltd | Processos de síntese e/ou purificação de compostos diaminofenotiazínio |
| CN101820884B (zh) * | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| AU2008306688B2 (en) * | 2007-10-03 | 2014-05-22 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| WO2010021755A2 (fr) * | 2008-08-20 | 2010-02-25 | Oligomerix, Inc. | Compositions de protéase tau et procédés |
| ES2540536T3 (es) | 2008-09-23 | 2015-07-10 | Wista Laboratories Ltd. | Ligandos para moléculas tau agregadas |
| WO2010067078A2 (fr) * | 2008-12-10 | 2010-06-17 | Wista Laboratories Ltd. | Sels de xanthylium disubstitués en 3 et 6 |
| US8691979B2 (en) | 2009-05-12 | 2014-04-08 | Wista Laboratories Ltd. | Methods of chemical synthesis of diaminophenothiazinium compounds involving the use of persulfate oxidants |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| EP2470211B1 (fr) * | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Anticorps liant les oligomères de la protéine tau |
| PT3792254T (pt) | 2009-09-24 | 2023-10-19 | Wista Lab Ltd | Hidratos de cloreto de metiltionínio cristalino |
| JP5868955B2 (ja) | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| WO2012051498A2 (fr) | 2010-10-15 | 2012-04-19 | The Board Of Regents Of The University Of Texas System | Anticorps qui lient des oligomères amyloïdes |
| JP6093707B2 (ja) | 2010-11-30 | 2017-03-08 | ウィスタ ラボラトリーズ リミテッド | 化合物製剤 |
| ES2714692T3 (es) | 2011-01-31 | 2019-05-29 | Tau Bio Logic Corp | Tratamiento de tauopatías |
| EA025033B1 (ru) | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| EP2699241B1 (fr) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Composés antiviraux |
| LT2885010T (lt) | 2012-08-16 | 2020-04-27 | Ipierian, Inc. | Tautopatijos gydymo būdai |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US9988418B2 (en) * | 2013-02-06 | 2018-06-05 | Agency For Science, Technology And Research | Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations |
| GB201317702D0 (en) | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| US10765755B1 (en) | 2013-11-20 | 2020-09-08 | University Of South Florida | Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies |
| JP2017505756A (ja) * | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | 可溶性高分子量（ｈｍｗ）タウ種およびその用途 |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| GB201512678D0 (en) | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| EP4335517A2 (fr) | 2016-07-25 | 2024-03-13 | WisTa Laboratories Ltd. | Administration et dosage de diaminophénothiazines |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| CA3107349A1 (fr) * | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methodes de traitement de troubles neurologiques |
| EP3826650A4 (fr) | 2018-07-23 | 2022-07-27 | Enclear Therapies, Inc. | Méthodes de traitement de troubles neurologiques |
| EP4364801A2 (fr) | 2018-07-26 | 2024-05-08 | WisTa Laboratories Ltd. | Dosage optimisé de diaminophénothiazines dans des populations |
| WO2020201828A1 (fr) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anticorps anti-tauc3 et leurs utilisations |
| AU2020271894A1 (en) | 2019-04-11 | 2021-12-02 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
| GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| GB202010620D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | System |
| WO2023232764A1 (fr) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Traitement de troubles neurodégénératifs à l'aide de composés contenant du méthylthioninium (mt) |
| WO2024063700A1 (fr) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Formulation orale de diaminophénothiazines et procédés de fabrication et d'utilisation de celle-ci dans le traitement et/ou la prévention de maladies |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (fr) * | 1957-07-17 | |||
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| EP0397687B1 (fr) | 1987-12-21 | 1994-05-11 | The University Of Toledo | Transformation par l'agrobacterium de graines de plantes de germination |
| US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| WO1993001348A1 (fr) | 1991-07-10 | 1993-01-21 | Minnesota Mining And Manufacturing Company | Compositions de traitement fluorochimique impermeables a l'eau et a l'huile |
| EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
| WO1993003177A1 (fr) | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Nouvelles proteines kinases a neurofilament et tau |
| DE69230148T2 (de) | 1991-12-06 | 2000-05-04 | Max Planck Gesellschaft | Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit. |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| AU708682B2 (en) | 1994-08-08 | 1999-08-12 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5693638A (en) * | 1996-02-23 | 1997-12-02 | Myers; Daniel | Method of treating a migraine headache |
| WO1999062548A1 (fr) * | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Procedes et compositions pour le diagnostic des pathologies tau |
| FR2788436A1 (fr) | 1999-01-14 | 2000-07-21 | Pf Medicament | Composition d'un derive de phenothiazine |
| WO2001053340A2 (fr) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Modele murin transgenique de maladies neurodegeneratives humaines |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
-
2001
- 2001-01-15 GB GBGB0101049.5A patent/GB0101049D0/en not_active Ceased
-
2002
- 2002-01-15 EP EP10007601A patent/EP2305823B1/fr not_active Expired - Lifetime
- 2002-01-15 AT AT02715498T patent/ATE483814T1/de active
- 2002-01-15 CN CN028063015A patent/CN1496404B/zh not_active Expired - Lifetime
- 2002-01-15 EP EP02715498A patent/EP1352077B1/fr not_active Expired - Lifetime
- 2002-01-15 WO PCT/GB2002/000153 patent/WO2002055720A2/fr active Application Filing
- 2002-01-15 ES ES10007601T patent/ES2407204T3/es not_active Expired - Lifetime
- 2002-01-15 AU AU2002225147A patent/AU2002225147B2/en not_active Expired
- 2002-01-15 DK DK02715498.8T patent/DK1352077T3/da active
- 2002-01-15 US US10/451,782 patent/US7335505B2/en not_active Expired - Lifetime
- 2002-01-15 JP JP2002556766A patent/JP4422407B2/ja not_active Expired - Lifetime
- 2002-01-15 DE DE60237874T patent/DE60237874D1/de not_active Expired - Lifetime
- 2002-01-15 ES ES02715498T patent/ES2353202T3/es not_active Expired - Lifetime
- 2002-01-15 PT PT100076017T patent/PT2305823E/pt unknown
- 2002-01-15 PT PT02715498T patent/PT1352077E/pt unknown
- 2002-01-15 DK DK10007601.7T patent/DK2305823T3/da active
- 2002-01-15 CA CA2697520A patent/CA2697520C/fr not_active Expired - Lifetime
- 2002-01-15 CA CA2434067A patent/CA2434067C/fr not_active Expired - Lifetime
-
2003
- 2003-10-30 HK HK03107838.8A patent/HK1055605A1/xx not_active IP Right Cessation
-
2008
- 2008-01-28 US US12/010,649 patent/US7893054B2/en not_active Expired - Fee Related
- 2008-07-22 JP JP2008188134A patent/JP5160990B2/ja not_active Expired - Lifetime
-
2011
- 2011-04-14 HK HK11103782.3A patent/HK1149588A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2305823B1 (fr) | 2013-03-27 |
| WO2002055720A9 (fr) | 2002-12-27 |
| EP1352077B1 (fr) | 2010-10-06 |
| JP2009035549A (ja) | 2009-02-19 |
| US20090075984A1 (en) | 2009-03-19 |
| JP4422407B2 (ja) | 2010-02-24 |
| CA2434067C (fr) | 2010-06-22 |
| CN1496404B (zh) | 2011-10-19 |
| DE60237874D1 (de) | 2010-11-18 |
| ES2353202T3 (es) | 2011-02-28 |
| DK2305823T3 (da) | 2013-06-24 |
| CA2697520C (fr) | 2014-02-04 |
| HK1149588A1 (en) | 2011-10-07 |
| EP1352077A2 (fr) | 2003-10-15 |
| JP5160990B2 (ja) | 2013-03-13 |
| CA2697520A1 (fr) | 2002-07-18 |
| US7335505B2 (en) | 2008-02-26 |
| JP2004524831A (ja) | 2004-08-19 |
| ATE483814T1 (de) | 2010-10-15 |
| US20040110250A1 (en) | 2004-06-10 |
| ES2407204T3 (es) | 2013-06-12 |
| US7893054B2 (en) | 2011-02-22 |
| EP2305823A1 (fr) | 2011-04-06 |
| CA2434067A1 (fr) | 2002-07-18 |
| CN1496404A (zh) | 2004-05-12 |
| PT1352077E (pt) | 2011-01-12 |
| GB0101049D0 (en) | 2001-02-28 |
| PT2305823E (pt) | 2013-07-08 |
| WO2002055720A3 (fr) | 2002-11-21 |
| AU2002225147B2 (en) | 2006-12-07 |
| WO2002055720A2 (fr) | 2002-07-18 |
| DK1352077T3 (da) | 2011-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1149588A1 (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| ATE280240T1 (de) | Enzymatische verfahren zur aüftrennüng von enantiomeren-mischungen nützlich als zwischenprodukte zur herstellung von taxanen | |
| MXPA04006082A (es) | Matriz de proteina maleable y usos de la misma. | |
| HUP0002189A2 (hu) | Eljárás oldalláncukban módosított epotilonok előállítására és az így előállított vegyületek | |
| DE59609733D1 (de) | Die verwendung von zinn-katalysatoren sowie vernetzbare mischungen, diese katalysatoren enthaltend | |
| CS38989A2 (en) | Method of phenoxyacetamidoderivative production | |
| IT1217899B (it) | Processo catalitico per la produzione di ossime | |
| ATE64548T1 (de) | Granuliertes produkt. | |
| ATE108777T1 (de) | Substituierte (chinolin-2-yl-methoxy)phenyl-acyl- sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln. | |
| ATE198840T1 (de) | Mobile vorrichtung zur herstellung von wässrigen flüssigfarben aus pulverförmigen bestandteilen und wasser | |
| ATE260096T1 (de) | Agglomerate durch kristallisation | |
| ATE311476T1 (de) | Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) | |
| MY137089A (en) | Materials and methods relating to protein aggregation in neurodegenerative disease | |
| WO2003004681A3 (fr) | Molecules d'acides nucleiques codant une serine protease 20 transmembranaire, les polypeptides codes et les methodes correspondantes | |
| BR9913720A (pt) | Processo de purificação por cristalização ourecristalização de ácidos carboxìlicos | |
| ATE199559T1 (de) | N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfür geeignetes diagnostisches mittel | |
| EP0261403A3 (fr) | Polypeptide de rhinovirus souche HRV89, et molécule d'ADN qui l'encode | |
| ATE539051T1 (de) | Verfahren zur herstellung von n-methyl pyrrolidon unter verwendung von gamma butyrolacton und gemischten methylaminen als ausgangssubstanzen | |
| DE50200885D1 (de) | Verfahren zur Herstellung von 1,4-Diaminonaphthalin und/oder 1,5-Diaminonaphthalin | |
| ES2016975B3 (es) | Compuestos quimicos. | |
| JPS6425759A (en) | 2,6-dichloropyridine derivative | |
| Martins et al. | Evolution of the jigs plant Morro Agudo Mine | |
| DE69819842D1 (de) | Süssstoffmischung, welche Neohesperidin-dihydrochalcon und mindestens einen weiteren Süssstoff enthält | |
| HUP0102540A2 (hu) | Új angiotenzin-receptor, eljárás előállítására és alkalmazása | |
| Morinaga et al. | The Kolbe-Schmitt reaction in aqueous solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20220114 |